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We report the case of a 62-year-old lady in whom adiagnosis of malignant thymoma was made after pre-
sentation with cognitive symptoms. These symptoms oc-
curred as a result of paraneoplastic limbic encephalitis (PLE),
which was diagnosed as a result of magnetic resonance
imaging (MRI) of the head.
CASE REPORT
A 62-year-old lady was referred to neurology with a
6-month history of short-term memory loss and uncharacter-
istic behavior. She had previously been fit and well, with no
significant medical problems. A formal Mini Mental State
Examination revealed a reduced score (23/30) consistent with
severe cognitive impairment.
Baseline hematological and biochemical investigations
were normal, a computed tomography (CT) scan of the brain
was thought to show frontal atrophy, and a provisional
diagnosis of Alzheimer disease was made. However, in view
of the rapid history and young age of the patient, she was
admitted for further investigation.
A lumbar puncture was performed; analysis of cerebro-
spinal fluid demonstrated an elevated protein level (67 mg/
100 ml) and the presence of oligoclonal bands.
Antineuronal antibodies were performed, which were
all negative (antineuronal nuclear antibodies (Hu/Ri), anti-
Purkinje cell antibodies (Yo), and antivoltage gated potas-
sium channel antibodies).
MRI of her brain revealed changes consistent with
limbic encephalitis (Figure 1).
In view of the concern that this was a paraneoplastic
process, a CT scan of the chest, abdomen, and pelvis was
performed to search for an underlying occult malignancy.
This revealed an anterior mediastinal mass with deposits seen
in the pleura (Figure 2).
The mediastinal mass was excised by video-assisted
anterior mediastinotomy. The pleural metastases were not
biopsied. Histology revealed lymphoepithelioma-like carci-
noma of the thymus (World Health Organization type C), and
a formal diagnosis of PLE secondary to a stage IVa thymic
cancer was made.
The patient was asymptomatic from her thoracic dis-
ease, and treatment was primarily aimed at improving her
cognitive function. Neither tumor excision nor plasma ex-
change had provided any improvement to her mental state.
She then went on to have cytotoxic chemotherapy with
500 mg/m2 of cyclophosphamide, 50 mg/m2 of doxorubicin,
and 50 mg/m2 of cisplatin on a thrice-weekly dosing cycle.
After three cycles, a repeat CT scan was performed, and a
15% to 20% reduction in the size of the pleural deposits
scan was reported. Chemotherapy was discontinued be-
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FIGURE 1. Magnetic resonance imaging axial flair demon-
strates bilateral increased signal in both hippocampi. More
extensive similar changes were demonstrated on other im-
ages on the left side extending to trigone and up to the
level of the corpus callosum.
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cause she had tolerated it poorly, and no cognitive im-
provement was noted.
She then received four cycles of rituximab (375 mg/m2)
at 1-week intervals, with two further cycles at once-monthly
intervals. However, no further improvement in her mental
state was observed. At the time of writing, she remains in the
community, debilitated by persistent, progressive cognitive
impairment.
DISCUSSION
Paraneoplastic neurological syndromes may be defined
as disorders of the nervous system that occur as a result of
malignancy but are not caused by direct tumor growth,
metastases, or metabolic or infectious complications.
PLE is a rare syndrome that affects the mesial temporal
lobe and limbic mesial cortical structures, causing memory
loss, personality changes, and seizures.1
PLE has been associated with a number of different
malignancies, most commonly small-cell lung cancer,2 but it
has been previously described in association with thymic
carcinoma.3
The pathogenesis of PLE is uncertain, but the current
accepted hypothesis is that of an immune-mediated response
against the nervous system.1
Diagnosis remains difficult. MRI is commonly abnor-
mal, with increased T2 and flair signals in the mesial tempo-
ral lobe. Electroencephalography is usually abnormal, with
slow-wave abnormalities and epileptiform activity involv-
ing the temporal lobe.4 A wide spectrum of neuronal
autoantibodies may be present, including anti-HU,5 anti-
TR,6 anti-MA2,7 and anti-CRMP-5 (previously demon-
strated in thymoma-related autoimmunity).8
Treatment of PLE may be aimed at the underlying
malignancy or at the antineuronal antibodies suspected of
mediating the disease process. The latter may be achieved
through intravenous immunoglobulins, plasma exchange,9 or
immunosuppression. Rituximab, a monoclonal antibody di-
rected against B lymphocytes expressing the CD20 antigen,
has been used in the treatment of PLE as an immunosuppres-
sant; in an uncontrolled trial of nine patients, there was
objective cognitive improvement in four of the patients (one
of these patients showed a dramatic improvement).10
In this case, PLE is clearly demonstrated by increased
signal intensity in the hippocampi as part of the mesial
temporal lobe on MRI of the brain. An underlying thymic
malignancy was diagnosed, but cognitive impairment has
persisted despite removal of the bulk of the tumor and various
attempts at immunosuppression.
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FIGURE 2. A computed tomography scan of the chest
demonstrates a 2.6-cm anterior mediastinal mass. Other
images demonstrated irregular pleural thickening.
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